SPRO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
-100.0%
258.0K
-99.4%
41.3M
+658.9%
5.4M
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
-100.0%
258.0K
-99.4%
41.3M
+658.9%
5.4M
Operating Expenses
41.9M
+322.3%
9.9M
+27.3%
7.8M
-21.2%
9.9M
-25.9%
13.4M
R&D
38.2M
+1012.3%
3.4M
+18.0%
2.9M
-48.0%
5.6M
-35.0%
8.6M
SG&A
3.7M
-42.7%
6.5M
+32.8%
4.9M
+13.7%
4.3M
+3.0%
4.2M
Operating Income
-41913000
-322.3%
-9926000
-31.7%
-7538000
-124.0%
31.4M
+496.7%
-7916000
EBITDA
-41913000
-322.3%
-9926000
-31.7%
-7538000
-124.0%
31.4M
+528.5%
-7329000
Net Income
-44278000
-363.5%
-9552000
-32.6%
-7203000
-122.9%
31.5M
+527.0%
-7382000
EPS (Basic)
$-0.76
-375.0%
$-0.16
-23.1%
$-0.13
-123.2%
$0.56
+530.8%
$-0.13
EPS (Diluted)
$-0.76
-375.0%
$-0.16
-23.1%
$-0.13
-128.3%
$0.46
+453.8%
$-0.13
Shares (Diluted)
58.2M
+0.4%
58.0M
+1.2%
57.3M
-16.3%
68.5M
+21.7%
56.3M
Spero Therapeutics (SPRO) — Financials